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ABSTRACT 
Different lipid based vesicular systems have been developed as controlled and targeted drug delivery systems. Pharmacosomes are 
novel vesicular drug delivery systems. They are potential alternative to conventional vesicles. Pharmacosomes are the amphiphilic 
phospholipids complexes of drugs bearing active hydrogen that bind to phospholipids. Similar to other vesicular systems 
pharmacosomes provide an efficient method for delivery of drug directly to the site of infection, leading to reduction of drug 
toxicity with no adverse effects. They also reduce the cost of therapy by improving bioavailability of medication, especially in the 
case of poorly soluble drugs. This approach as a drug delivery system certainly promises a reliable, safe, selective and precise 
method of drug delivery.  They help in controlled release of drug at the site of action as well as in reduction in cost of therapy, 
drug leakage and toxicity, increased bioavailability of poorly soluble drugs, and restorative effects. They are mainly prepared by 
hand-shaking and ether injection method. The Pharmacosomes have evaluated for different parameters such as size, surface 
morphology and in vitro release rate. This article reviews the potential of pharmacosomes as controlled and targeted drug delivery 
systems and highlights the methods of preparation and characterization.  
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INTRODUCTION 
Many researchers have been working on novel drug 
delivery system for the past few decades, with an aim 
to further develop this system.  The main purpose for 
the development of novel drug delivery systems can be 
explained in on the basis of clinical advantages of these 
systems, and their economic aspects
1
. An ideal novel 
drug delivery system should fulfill two prerequisites: 
firstly, it should deliver the drug at rate directed by the 
body requirements, secondly; it should channel the 
active entity to the target site of action
2
. One of the 
approaches to modify the original biodistribution of 
drugs is to entrap them in submicroscopic drug carriers 
such as liposomes, transferosomes, niosomes, 
polymeric nanoparticles, serum proteins, 
immunoglobulins, microspheres, erythrocytes, reverse 
micelles, monoclonal antibodies, and pharmacosomes
3
. 
In the recent years, lipid vesicles were found to be of 
importance in the field of immunology, membrane 
biology, diagnostic techniques and most recently 
genetic engineering
4
. Vesicular structures are such 
system that prolong the duration of the drug in 
systemic circulation, and reduce the toxicity by 
selective uptake
5
.  These vesicles were first reported in 
1965 by Bingham, and were given the name “Bingham 
bodies” which play a major role in modeling biological 
membranes, and in the transport and targeting of active 
agents
6
.  
 
Figure 1: Pharmacosomes 
These are defined as colloidal dispersions of drugs 
covalently bound to lipids and may exist as ultrafine 
vesicular, micellar or hexagonal aggregates, depending 
on the chemical structure of drug-lipid complex
7
. 
These systems are formed by linking a drug 
(pharmakon) to a carrier (soma), so they are called 
pharmacosomes. After absorption, their velocity of 
degradation into active drug molecule depends to a 
great extent on the size and functional groups of drug 
molecule, the chain length of the lipids and the spacer.  
Advantages
 
Since the drug is covalently linked to the carrier, no 
leakage of drug takes place
8
. 
1. Entrapment efficiency is high and not affected 
by encaptured volume and drug-bilayer 
interactions
9
. 
2. Suitable for both hydrophilic and lipophilic 
drugs.  
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3. No problem is associated with drug 
incorporation
10
.  
4. The physicochemical stability of the 
pharmacosomes depends upon the 
physicochemical properties of the drug- lipid 
complex
11
.  
5. Drug can be delivered directly to the site of 
action. 
6. It improves bioavailability especially in case 
of poorly soluble drugs. 
7. No need of removing the free unentrapped 
drug from the formulation as needed in case of 
liposomes. 
8. There is reduction in adverse effects and 
toxicity. 
9. There is reduction cost of therapy. 
Limitations
 
Synthesis of a compound depends upon its amphiphilic 
nature.  
1. It requires surface and bulk interaction of 
lipids with drugs
12
.  
2. It requires covalent bonding to protect the 
leakage of drugs.  
3. On storage, there is fusion and aggregation, as 
well as chemical hydrolysis
13
.  
 
COMPONENTS OF PHARMACOSOMES 
For this delivery system the three components are 
drugs, solvent and carriers (lipid).  
1. Drugs  
Any drug having an active hydrogen atom (-COOH, -
OH,-NH2 etc) can be esterified to the lipid, with or 
without spacer chain resulting into amphiphilic 
complexes. These synthesized amphiphilic complexes 
(pharmacosomes), facilitate membrane, tissue, or cell 
wall transfer, in the organism
18
.  
2. Lipids 
 Phospholipids are principal molecular building block 
of cell membranes. Two type of phospholipids 
generally used are phosphoglycerides and spingolipids. 
The most common phospholipid is phosphotidyl 
choline molecule
19
.  
3. Solvent 
 Organic solvent of analytical grade and intermediate 
polarity is used in development of pharmacosomes. It 
must be of high purity and volatile in nature. The 
phospholipids and the drug must be dissolved in the 
selected solvent. The selection of solvent depends on 
polarity of the drug and the lipid
20
.  
 
METHODS OF PREPARATION 
 
1.  Ether injection method 
In this method solution containing drug-lipid complex 
is mixed properly and is slowly injected into a hot 
aqueous medium through gauze needle and vesicles 
form readily
21
.  
2. Solvent evaporation method/ hand shaking 
method 
Mixture of drug and lipid is dissolved in a volatile 
organic solvent. Thereafter solvent is evaporated using 
rotatory evaporator in round bottom flask which leaves 
a thin film of solid mixture deposited on the walls of 
flask. The dried film hydrates with aqueous medium 
and readily gives a vesicular suspension
22
.  
3. Anhydrous co-solvent lyophilization method: 
First of all drug and phospholipids are dissolved in 
solution of dimethyl sulfoxide containing glacial acetic 
acid. Then mixture is agitated to get clear liquid and 
then freeze-dried overnight at condenser temperature. 
The resultant complex is flushed with nitrogen and 
stored at 4
o
C
23
.  
4. Supercritical fluid process  
Drug and lipid complex are dissolved in a supercritical 
fluid of CO2, then mix into nozzle mixing chamber.  
 
EVALUATION OF PHARMACOSOMES 
1. Complex Determination  
The formation of complex and conjugate can be 
determined by the correlation spectrum observed in 
complex sample with that of discrete constituents and 
also with their mixture with the help of FTIR 
spectrum
24
. 
2. Surface morphology  
With the help of scanning electron microscopy (SEM) 
or transmision electron microscopy (TEM), the surface 
morphology can be observed. Purity grades of 
phospholipid affected to shape and size of 
pharmacosome and the process variables such as speed 
of rotation, vaccum applied or the method used. 
3. Drug content  
To determine the drug content in drug-pc complex, 
coplex equivalent to drug weighed and added into 
volumetric flask with suitable solvent. The solution is 
mixed by means of magnetic stirrer. After 24 hrs 
suilatble dilution drug content is determined UV 
spectrophotometrically
25
.  
4. Differential scanning calorimetry (DSC)  
This thermal analytical technique is used to determine 
the drug-excipients compatibility or interactions. The 
interaction can be concluded by the elimination 
endothermic peaks, appearance of peaks and change in 
peak shape and its onset, peak temperature /melting 
point and relative peaks area or enthalpy.  
5. X-ray power diffraction (XRPD) 
 It is performed to detremine the degree of crystallinity 
by using the relative integrated intensity of reflection 
peaks. The itegrated intensity is given by the area 
under curves of the XRPD patterns and it represents the 
specimen charetristics
26
.  
6. Fourier transforms infrared spectroscopy (FTIR)  
With the help of IR spectroscopy the formation of 
complex can be confirmed by comparing the spetrum 
of complex with the spectrum of individual 
components and their mechanical mixture.   
7. In-vitro Study 
 Depending upon the expected therapeutic activity of 
biologically active constituents, model of in–vivo and 
in- vitro evaluation is carried out.  
Application of pharmacosomes  
Pharmacosomes demonstrate a wider stability profile 
and greater shelf life. They have the capacity to 
augment drug absorption and its transport. 
Pharmacosomes can improve the rate of permeation by 
improving the membrane fluidity. The transition 
temperature of vesicles in the form of vesicles and 
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micelles might pose an evident effect on vesicular 
interaction with biomembrane, hence improving the 
transfer of drug across membrane. This approaches has 
been successfully used by many researchers to improve 
the therapeutic performance of various drug  
Such as pindolol diglyceride, amoxicillin, taxol, 
cytarbin, dermatansulfate, bupranolol hydrochloride 
etc. In a study Yue et al. optimized the formulated 
geniposide pharmacosomes and examined their 
attributes. Pharmacosomes have greater degree of 
selectivity for action on specific target cells
27.
  In a 
study Raikhman et al. described pharmacosomes as 
building particles capable of transporting biologically 
active substances including nucleic acids and 
proteins
28
. 
Semalty et al. developed and evaluated diclofenac 
pharmacosome, and it was found that solubility was 
enhanced in pharmacosomes (22.1 g/ mL) as compared 
to diclofenac (10.5 g/mL). Drug release was also 
improved from 60.4% of diclofenac to 87.8% of 
diclofenac pharmacosomes after 10 hrs of dissolution 
study
29
. Zhang et al. developed and evaluated 
pharmacosomes of 3’, 5’-dioctanoyl-5- fluoro- 2’-
deoxyuridine using central composite design,  and 
observed good targeting efficiency of pharmacosomes 
in vivo and improved drug potential to pass through 
blood  brain barrier
30
. In a study Yi-Guang et al. 
prepared acyclovir pharmacosomes and observed that 
the plasma proteins in blood absorbed pharmacosomes 
and interfered with the interactions of erythrocytes and 
hence reduced haemolytic reaction
 31
. 
 
CONCLUSION 
There are many limitations that are associated with 
vesicular drug delivery systems, like other vesicular 
system pharmacosomes plays an important role in the 
selective targeting, and the controlled delivery. 
Pharmacosomes have immense potential, and 
advantages over other vesicular systems. The influence 
of spacer groups and linkages should be observed more 
rigorously for further improvement in drug fate and 
biological activity of the drug to achieve the 
therapeutic goal. The system requires greater efforts 
towards investigating the non-bilayer phases and 
exploring the mechanism of action. Pharmacosomes do 
not have only high entrapment efficiency but delivery 
can be predetermined, because drug itself in 
conjugation with lipids forms vesicles. Since 
pharmacosomes have immense potential, there is need 
of more work to be done on this system to get more 
fruitful results. 
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Table 1: Comparison of conventional vesicular systems and pharmacosomes 
Vesicular 
system 
Limitations Pharmacosomes 
Niosomes Drug leaching, time consuming , 
less stable 
More stable, more 
efficient
15 
Liposomes Expensive, degradation by 
oxidation, 
sedimentation, leaching 
of drug
14 
Cheaper to prepare, 
entrapment efficiency is 
independent of inclusion 
volume and drugbilayer 
interactions, covalent 
linkage prevent drug 
leakage, oxidation 
resistant and pure and 
natural phospholipids 
not needed
16
. 
Transferosomes Expensive, oxidative 
degradation, lack of 
purity of natural 
phospholipids. 
Cheaper ,oxidation 
resistant, pure  and 
natural phospholipids 
not needed
17 
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